Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiao'er Haoqin Kanggan Granules is a Traditional Chinese Medicine (TCM) botanical formulation developed by Suzhou Yusen New Drug Development Co., Ltd. It is specifically designed for the treatment of acute upper respiratory tract infections in children, particularly those diagnosed with the "wind-heat with dampness" syndrome (风热夹湿证) according to TCM principles. The name suggests the inclusion of *Artemisia annua* (Hao) and *Scutellaria baicalensis* (Qin), which are traditionally used to clear heat and resolve dampness. The drug is currently undergoing clinical evaluation in China to establish its safety and efficacy profile in the pediatric population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiao'er Haoqin Kanggan Granules.